Janux Therapeutics (JANX) - BMS Collaboration Milestone

JANX Price: $13.90 (3/31/26 close) | Pre-market: $13.98 (+0.57%)Market Cap: ~$846M

The Deal

Bristol Myers Squibb triggered a $35M milestone payment to Janux for nominating a development candidate under their existing collaboration. The candidate is a tumor-activated therapeutic built on Janux's TRACTr platform, targeting an undisclosed solid tumor antigen expressed across several cancer types.

Janux handles preclinical development through IND submission. BMS holds the IND and takes over clinical development and global commercialization. Janux stays involved through completion of Phase 1. Additional development, regulatory, commercial milestones plus tiered royalties on global sales still on the table.

The Pipeline

Three clinical candidates running. JANX007 (TRACTr, PSMA-targeting) in Phase 1 for metastatic castration-resistant prostate cancer. JANX008 (TRACTr, EGFR-targeting) in Phase 1 for multiple solid tumors. JANX011 (ARM platform, CD19) in Phase 1 for autoimmune diseases, first patient dosed February 2026.

Plus the BMS collaboration candidate now entering IND-enabling studies, and additional TRACTr, TRACIr, and ARM programs in earlier development.

Why It Matters

$35M milestone is more meaningful at $846M market cap than I originally wrote. That's real cash for a company burning $155M TTM on an EBITDA basis. Current ratio of 39x means they're sitting on a big cash pile relative to current liabilities, so no liquidity pressure.

The bigger signal is BMS continuing to advance the collaboration. Large pharma doesn't nominate development candidates on programs they plan to abandon. This validates the TRACTr platform and keeps the partnership pipeline moving toward IND and eventually clinical data. BMS is one of the most active oncology acquirers in the market.

Stock is down 61% from its 52-week high of $35.34. Trading at $13.90 with BMS validation, three Phase 1 programs, and a platform story across oncology and autoimmune. The $35M payment plus future milestones and royalties add meaningful non-dilutive capital.

Next earnings May 7.